Citations

Showing 10 of 108135 citations.

Oral idasanutlin in patients with polycythemia vera
Mascarenhas, John , Lü, Min , Virtgaym, Elizabeth, Xia, Lijuan, Sandy, Lonette, Petersen, Bruce , Farnoud, Noushin , Najfeld, Vesna , Rampal, Raajit K. , Dueck, Amylou C. , Dueck, A. C. , Mascarenhas, John , Najfeld, Vesna , Kosiorek, Heidi , Mesa, Ruben A. , Hoffman, Ronald

Mayo Clinic

Blood | June 5, 2019 | Volume: 134 | Issue: 6 | Pages: 525-533

10.1182/blood.2018893545 | PMID 31167802 Get It

Abstract A limited number of drugs are available to treat patients with polycythemia vera (PV) and essential thrombocythemia (ET). We attempted to identify alternative agents that may target abnormalities within malignant hematopoietic stem (HSCs) and progenitor cells (HPCs). Previously, MDM2 protein levels were shown to be upregulated in PV/ET CD34+ cells, and exposure to a nutlin, an MDM2 antagonist, induced activation of the TP53 pathway and selective depletion of PV HPCs/HSCs. This anticlonal activity was mediated by upregulation of p53 and potentiated by the addition of interferon-α2a (IFN-α2a). Therefore, we performed an investigator-initiated phase 1 trial of the oral MDM2 antagonist idasanutlin (RG7388; Roche) in patients with high-risk PV/ET for whom at least 1 prior therapy had failed. Patients not attaining at least a partial response by European LeukemiaNet criteria after 6 cycles were then allowed to receive combination therapy with low-dose pegylated IFN-α2a. Thirteen patients with JAK2 V617F+ PV/ET were enrolled, and 12 (PV, n = 11; ET, n = 1) were treated with idasanutlin at 100 and 150 mg daily, respectively, for 5 consecutive days of a 28-day cycle. Idasanutlin was well tolerated; no dose-limiting toxicity was observed, but low-grade gastrointestinal toxicity was common. Overall response rate after 6 cycles was 58% (7 of 12) with idasanutlin monotherapy and 50% (2 of 4) with combination therapy. Median duration of response was 16.8 months (range, 3.5-26.7). Hematologic, symptomatic, pathologic, and molecular responses were observed. These data indicate that idasanutlin is a promising novel agent for PV; it is currently being evaluated in a global phase 2 trial. This trial was registered at www.clinicaltrials.gov as #NCT02407080.
Comparison of 99mTc-Sestamibi Molecular Breast Imaging and Breast MRI in Patients With Invasive Breast Cancer Receiving Neoadjuvant Chemotherapy
Hunt, Katie N. , Conners, Amy Lynn , O’Connor, Michael K. , Weinshilboum, Richard, Wang, Liewei , Carter, Jodi M. , McLaughlin, Sarah A. , Aspitia, Alvaro Moreno, Gray, Richard J. , Northfelt, Don W., O'Connor, Michael K, Suman, Vera, Kalari, Krishna, Carter, Jodi, Northfelt, Don, Goetz, Matthew P. , Suman, Vera J. , Kalari, Krishna R. , Boughey, Judy C. , Carter, Jodi

Mayo Clinic

American Journal of Roentgenology | June 5, 2019 | Volume: 213 | Issue: 4 | Pages: 932-943

10.2214/ajr.18.20628 | PMID 31166752 Get It

The innate immune sensor Toll-like receptor 2 controls the senescence-associated secretory phenotype
Hari, Priya, Millar, Fraser R. , Tarrats, Núria , Birch, Jodie , Quintanilla, Andrea , Rink, Curtis, Fernández-Duran, Irene , Muir, Morwenna , Finch, Andrew J. , Brunton, Valerie G. , Passos, João F. , Morton, Jennifer P. , Boulter, Luke , Acosta, Juan Carlos , Passos, João F

Mayo Clinic

Science Advances | June 5, 2019 | Volume: 5 | Issue: 6 | Pages: No page available

10.1126/sciadv.aaw0254 | PMID 31183403 Get It

Innate immune sensing is essential for the proinflammatory program in cellular senescence.
When Generosity Harms Health Care and Public Health
Barwise, Amelia , Liebow, Mark , Barwise, Amelia K

Mayo Clinic

American Journal of Public Health | June 5, 2019 | Volume: 109 | Issue: 7 | Pages: 997-998

10.2105/ajph.2019.305073 | PMID 31166715 Get It

Laser Acupuncture: A Concise Review
Chon, Tony Y. , Mallory, Molly J., Yang, Juan , Bublitz, Sara E. , Do, Alexander , Dorsher, Peter T.

Mayo Clinic

Medical Acupuncture | June 5, 2019 | Volume: 31 | Issue: 3 | Pages: 164-168

10.1089/acu.2019.1343 | PMID 31297170 Get It

Diffuse Lewy Body Disease and Alzheimer Disease: Neuropathologic Phenotype Associated With the PSEN1 p.A396T Mutation
Gondim, Dibson , Oblak, Adrian L. , Murrell, Jill R. , Epperson, Francine, Ross, Owen A. , Ross, Owen A , Richardson, Rose M. , Ghetti, Bernardino

Mayo Clinic

Journal of Neuropathology & Experimental Neurology | June 5, 2019 | Volume: 78 | Issue: 7 | Pages: 585-594

10.1093/jnen/nlz039 | PMID 31165862 Get It

Eosinophils downregulate lung alloimmunity by decreasing TCR signal transduction
Onyema, Oscar Okwudiri , Guo, Yizhan , Mahgoub, Bayan , Wang, Qing , Manafi, Amir , Mei, Zhongcheng , Banerjee, Anirban , Li, Dongge , Stoler, Mark H. , Zaidi, Melissa T. , Schrum, Adam G. , Kreisel, Daniel , Jacobsen, Elizabeth A. , Krupnick, Alexander S. , Schrum, Adam G , Jacobsen, Elizabeth A , Gelman, Andrew E

Mayo Clinic

JCI Insight | June 5, 2019 | Volume: 4 | Issue: 11 | Pages: No page available

10.1172/jci.insight.128241 | PMID 31167966 Get It

Despite the accepted notion that granulocytes play a universally destructive role in organ and tissue grafts, it has been recently described that eosinophils can facilitate immunosuppression-mediated acceptance of murine lung allografts. The mechanism of eosinophil-mediated tolerance, or their role in regulating alloimmune responses in the absence of immunosuppression, remains unknown. Using lung transplants in a fully MHC-mismatched BALB/c (H2 d ) to C57BL/6 (H2 b ) strain combination, we demonstrate that eosinophils downregulate T cell–mediated immune responses and play a tolerogenic role even in the absence of immunosuppression. We further show that such downregulation depends on PD-L1/PD-1–mediated synapse formation between eosinophils and T cells. We also demonstrate that eosinophils suppress T lymphocyte responses through the inhibition of T cell receptor/CD3 (TCR/CD3) subunit association and signal transduction in an inducible NOS–dependent manner. Increasing local eosinophil concentration, through administration of intratracheal eotaxin and IL-5, can ameliorate alloimmune responses in the lung allograft. Thus, our data indicate that eosinophil mobilization may be utilized as a novel means of lung allograft–specific immunosuppression.
The hepatic WASH complex is required for efficient plasma LDL and HDL cholesterol clearance
Wijers, Melinde, Zanoni, Paolo , Liv, Nalan , Vos, Dyonne , Jäckstein, Michelle Y., Smit, Marieke , Wilbrink, Sanne, Wolters, Justina C. , Veen, Ydwine T. van der, Huijkman, Nicolette, Dekker, Daphne, Kloosterhuis, Niels , Dijk, Theo H. van , Billadeau, Daniel D. , Kuipers, Folkert , Kuivenhoven, Jan Albert , Sluis, Bart van de , van de Sluis, Bart , Klumperman, Judith , Eckardstein, Arnold von

Mayo Clinic

JCI Insight | June 5, 2019 | Volume: 4 | Issue: 11 | Pages: No page available

10.1172/jci.insight.126462 | PMID 31167970 Get It

The evolutionary conserved Wiskott-Aldrich syndrome protein and SCAR homolog (WASH) complex is one of the crucial multiprotein complexes that facilitates endosomal recycling of transmembrane proteins. Defects in WASH components have been associated with inherited developmental and neurological disorders in humans. Here, we show that hepatic ablation of the WASH component Washc1 in chow-fed mice increases plasma concentrations of cholesterol in both LDLs and HDLs, without affecting hepatic cholesterol content, hepatic cholesterol synthesis, biliary cholesterol excretion, or hepatic bile acid metabolism. Elevated plasma LDL cholesterol was related to reduced hepatocytic surface levels of the LDL receptor (LDLR) and the LDLR-related protein LRP1. Hepatic WASH ablation also reduced the surface levels of scavenger receptor class B type I and, concomitantly, selective uptake of HDL cholesterol into the liver. Furthermore, we found that WASHC1 deficiency increases LDLR proteolysis by the inducible degrader of LDLR, but does not affect proprotein convertase subtilisin/kexin type 9–mediated LDLR degradation. Remarkably, however, loss of hepatic WASHC1 may sensitize LRP1 for proprotein convertase subtilisin/kexin type 9–induced degradation. Altogether, these findings identify the WASH complex as a regulator of LDL as well as HDL metabolism and provide in vivo evidence for endosomal trafficking of scavenger receptor class B type I in hepatocytes.
The Effects of Cigarette Smoking Extracts on Cell Cycle and Tumor Spread: Novel Evidence
Citarella, Fabrizio , Croghan, Ivana T. , Croghan, Ivana, Pezzuto, Aldo , Tonini, Giuseppe , Citarella, Fabrizio

Mayo Clinic

Future Science OA | June 5, 2019 | Volume: 5 | Issue: 5 | Pages: No page available

10.2144/fsoa-2019-0017 | PMID 31205749 Get It

Impact of Measurement Error on Predicting Population-Based Inpatient Glucose Control
Saulnier, George E., Castro, Janna C. , Cook, Curtiss B.

Mayo Clinic

Future Science OA | June 5, 2019 | Volume: 5 | Issue: 5 | Pages: No page available

10.2144/fsoa-2019-0003 | PMID 31363420 Get It